The 6th ALS Drug Development Summit is dedicated to innovating a new era of earlier diagnosis & prognosis to advance stratification of heterogeneous ALS populations.
Key Topics
Assessing Neurofilament Light Changes in Presymptomatic Sporadic ALS
Promising Longer-Term Biomarker Data from NurOwn Program in ALS: Spotlight on NfL in EAP Extension Cohort
Developing Robust In Vitro Assays to Mimic Complex ALS Pathologies
Innovating More Objective Biomarkers to Transform Clinical Assessments of ALS Severity
Navigating the Complexity of Causative Genes & Risk Factors for ALS to Give Rise to Next-Generation Targets
Modernizing the Clinical Trial Approach as More Treatments Emerge & Endpoints Evolve
Revitalizing ALS Drug Development to More Effectively Meet the Requirements of People Living with ALS
Navigating Commercial Bottlenecks to Determine Access to Treatment for People Living with ALS
Revitalizing In Vivo Models for Replicating Motor Neuronal Pathologies
Reviewing the Latest Preclinical Progress of Novel ALS Targets
Keeping Pace with the Evolving Approval Landscape for ALS Therapeutics
Exploring Emerging Clinical ALS Pipeline Innovation
Future Directions & Research Priorities: What Will the ALS Landscape Look Like in Years to Come?
Who should Attend
Head of Neuroscience Experimental Medicine, Takeda Pharmaceutical Co. Ltd.
Co-CEO, BrainStorm Cell Therapeutics
Head of Target Validation, AcuraStem Inc.
Senior Scientist, Sanofi
VP and Global Head Medical Affairs, Amylyx Pharmaceuticals
Director - Computational Biology, Prevail Therapeutics
Principle Scientist II, Novartis AG
Associate Director, Regeneron Pharmaceuticals Inc
Vice President & Head of Clinical Development, QurAlis Corp.
Vice President of Research and Development, NeuroSense Therapeutics
Advocate, I AM ALS
Nurse Practitioner & Healey & AMG Center for ALS Research Site Director, Massachusetts General Hospital (MGH) and Harvard Medical School
